Tesara

GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations
Endpoints
Wed, 04/29/20 - 10:45 pm
GSK
Zejula
Tesara
FDA
ovarian cancer